Telomere maintenance mechanisms in liposarcomas: Association with histologic subtypes and disease progression

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8918-8924

  Costa, Aurora ^a   Daidone, Maria Grazia ^a   Daprai, Laura ^a   Villa, Raffaella ^a   Cantù, Sabrina ^a   Pilotti, Silvana ^a   Mariani, Luigi ^a   Gronchi, Alessandro ^a   Henson, Jeremy D ^b   Reddel, Roger R ^b   Zaffaroni, Nadia ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CHILDREN'S MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; HUMAN; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TELOMERE;

ADULT; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HUMANS; LIPOSARCOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; SURVIVORS; TELOMERE;

EID: 33748989558     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-0273     Document Type: Article

References (40)

1. Allsopp RC, Chang E, Kashefi-Aazam M, et al. Telomere shortening is associated with cell division in vitro and in vivo. Exp Cell Res 1995;220:194-200.
2. Harley CB, Vaziri H, Counter CM, et al. The telomere hypothesis of cellular aging. Exp Gerontol 1992; 27:375-82.
3. Shay JW, Zou Y, Hiyama E, et al. Telomerase and cancer. Hum Mol Genet 2001;10:677-85.
4. Bryan TM, Englezou A, Dalla-Pozza L, et al. Evidence for an alternative mechanism for mantaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997;3:1271-4.
5. Dunham MA, Neumann AA, Fasching CL, et al. Telomere maintenance by recombination in human cells. Nat Genet 2000;26:447-50.
6. Yeager TR, Neumann AA, Englezou A, et al. Telomerase-negative immortalized human cells contain a novel type of promyelocytic leukemia (PML) body. Cancer Res 1999;59:4175-9.
7. Ulaner GA, Huang HY, Otero J, et al. Absence of a telomere maintenance mechanism as a favorable prognostic factor in patients with osteosarcoma. Cancer Res 2003;63:1759-63.
8. Montgomery E, Argani P, Hicks JL, et al. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 2004;164:1523-9.
9. Hakin-Smith V, Jellinek DA, Levy D, et al. Alternative lengthening of telomeres and survival in patients with glioblastoma multiforme. Lancet 2003;361:836-8.
10. Henson JD, Neumann AA, Yeager TR, et al. Alternative lengthening of telomeres in mammalian cells. Oncogene 2002;21:598-610.
11. Blasco MA. Telomerase beyond telomeres. Nat Rev Cancer 2002;2:627-33.
12. Henson JD, Hannay JA, McCarthy SW, et al. A robust assay for alternative lengthening of telomeres in tumors shows the significance of alternative lengthening of telomeres in sarcomas and astrocytomas. Clin Cancer Res 2005;11:217-25.
13. Sandberg AA. Update on the cytogenetics and molecular genetics of bone and soft tissue tumors: liposarcoma. Cancer Genet Cytogenet 2004;155:1-24.
14. Johnson JE, Varkonyi RJ, Schwalm J, et al. Multiple mechanisms of telomere maintenance exist in liposarcomas. Clin Cancer Res 2005;11:5347-55.
15. Gronchi A, Casali PG, Fiore M, et al. Retroperitoneal soft tissue sarcomas: patterns of recurrence in 167 patients treated at a single institution. Cancer 2004;100: 2448-55.
16. Gronchi A, Casali PG, Mariani L, et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol 2005;23:96-104.
17. Fletcher CDM, Unni KK, Mertens F, editors. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press; 2002.
18. Villa R, Folini M, Perego P, et al. Telomerase activity and telomere length in human ovarian cancer and melanoma cell lines: correlation with sensitivity to DNA damaging agents. Int J Oncol 2000;16:995-1002.
19. Grant JD, Broccoli D, Muquit M, et al. Telometric: a tool providing simplified, reproducible measurements of telomeric DNA from constant field agarose gels. Biotechniques 2001;31:1314-6.
20. Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;66:2011-5.
21. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-220.
22. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-4.
23. Gupta J, Han LP, Wang P, et al. Development of retinoblastoma in the absence of telomerase activity. J Natl Cancer Inst 1996;88:1152-7.
24. Ulaner GA, Hoffman AR, Otero J, et al. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 2004;41:155-62.
25. Seger YR, Garcia-Cao M, Piccinin S, et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002;2:401-13.
26. Perrem K, Colgin LM, Neumann AA, et al. Coexistence of alternative lengthening of telomeres and telomerase in hTERT-transfected GM847 cells. Mol Cell Biol 2001;21:3862-75.
27. Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet 2001;10: 1945-52.
28. Grobelny JV, Kulp-McEliece M, Broccoli D. Effects of reconstitution of telomerase activity on telomere maintenance by the alternative lengthening of telomeres (ALT) pathway. Hum Mol Genet 2001;10:1953-61.
29. Stewart SA, Hahn WC, O'Connor BF, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A 2001; 99:12606-11.
30. Ford LR Zou Y, Pongracz K, et al. Telomerase can inhibit the recombination-based pathway of telomere maintenance in human cells. J Biol Chem 2001;276: 32198-203.
31. Keith WN. From stem cells to cancer: balancing immortality and neoplasia. Oncogene 2004;23:5092-4.
32. Serakinci N, Hoare SF, Kassem M, Atkinson SP, Keith WN. Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cells. Regenerative Med 2006;1:125-31.
33. Atkinson SP, Hoare SF, Glasspool RM, Keith WN. Lack of telomerase gene expression in alternative lengthening of telomere cells is associated with chromatin remodeling of hTR and hTERT gene promoters. Cancer Res 2005;65:7585-90.
34. Pilotti S, Della Torre G, Lavarino C, et al. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms. J Pathol 1997;181:14-24.
35. Knight JC, Renwick PJ, Cin PD, Van den Berghe H, Fletcher CD. Translocation t(12:16) (q13:p11) in myxoid and round cell liposarcoma: molecular and cytogenetic analysis. Cancer Res 1995;55:24-7.
36. Scheel C, Schaefer KL, Jauch A, et al. Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene 2001;20:3835-44.
37. Schneider-Stock R, Boltze C, Jager V, et al. Elevated telomerase activity, c-MYC-, and hTERT mRNA expression: association with tumour progression in malignant lipomatous tumours. J Pathol 2003;199:517-25.
38. Chang S, Khoo CM, Naylor ML, et al. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev 2003; 17:88-100.
39. Sun B, Chen M, Hawks CL, et al. Immortal ALT+ human cells do not require telomerase reverse transcriptase for malignant transformation. Cancer Res 2005;65:6512-5.
40. Reddel RR, Bryan TM. Alternative lengthening of telomeres: dangerous road less travelled. Lancet 2003; 361:1840-1.